98%
921
2 minutes
20
Psoriasis, a common chronic inflammatory skin disorder, encompasses various subtypes, including guttate, pustular, erythrodermic, and the most common type, plaque psoriasis. Irrespective of the subtype, psoriasis can manifest with multisystemic presentations, including psoriatic arthritis, metabolic disorders, cardiovascular disease, malignancies, chronic kidney disease (CKD), psychiatric illness, and inflammatory bowel disease (IBD). Many comorbidities and concomitant conditions must be considered when selecting the most appropriate therapy for a patient (Kaushik et al., 2019 and Monks et al., 2021) . Ongoing clinical trials and the development of new therapeutic targets contribute to the continuous improvement of available treatment options. Given the dynamic landscape of therapies, particularly when managing complex patients with multiple comorbidities, dermatologists are constantly challenged with the task of adeptly tailoring treatments to each psoriasis patient. This article systematically reviews the current evidence, presenting it as an updated Psoriasis Decision Tree to assist physicians in selecting tailored treatment options.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.17497 | DOI Listing |
JACC Heart Fail
September 2025
Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Eur J Gastroenterol Hepatol
September 2025
Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, Anqing, Anhui, China.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated death globally. Second-line therapies are crucial for improving survival and quality of life among individuals suffering from advanced HCC who have not responded to first-line therapies. This study sought to evaluate the safety and efficacy of different second-line therapies for advanced HCC by network meta-analysis.
View Article and Find Full Text PDFEur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.
Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.
View Article and Find Full Text PDFJ Cataract Refract Surg
July 2025
Helsinki Retina Research Group, University of Helsinki, Finland.
Topic: To compare the outcomes of surgical approaches to correct ametropia following cataract and lens surgery.
Clinical Relevance: Despite advancements in the field of biometry and intraocular lens (IOL) power calculation formulas, complete elimination of refractive surprises following cataract and lens surgery is impossible. Preferred Practice Patterns acknowledges the possibility of refractive surprise following cataract surgery; however, no recommendations regarding the preferred treatment have been given.
Adv Emerg Nurs J
September 2025
Author Affiliations: Emory University Hospital, Atlanta, Georgia (Drs Alvarez and Davis); and Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia (Dr Davis).
Acute abnormal uterine bleeding is a frequent reason for emergency department visits and, in severe cases, can become life-threatening. Tranexamic acid is a potential treatment option. However, its use in this setting remains under-researched.
View Article and Find Full Text PDF